At the news
? BULLISHIMPACT 8/10 8-K filed Mar 23, 2026 at 08:55 ET
Abbott Laboratories completed the acquisition of Exact Sciences for $105.00 per share in cash, establishing Abbott as a leader in cancer screening and diagnostics. The deal adds Exact Sciences' portfolio, including Cologuard and Oncotype DX, to Abbott's diagnostics business.
- Abbott completed the acquisition of Exact Sciences on March 23, 2026
- Exact Sciences shareholders received $105.00 per share in cash
- Exact Sciences is now a wholly owned subsidiary of Abbott
- The deal establishes Abbott as a leader in the $60 billion U.S. cancer screening and precision oncology diagnostics market
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access